Cardiovascular complications of phosphodiesterases-5 Inhibitors;Powiklania sercowo-naczyniowe inhibitorów fosfodiesterazy-5

Polski Merkuriusz Lekarski

Volumn 30, Issue 176, 2011, Pages 139-142

  Dworzanski W ^a   Jaskolska A ^a   Szumllo M ^a,b   Switalska A ^a   Burdan, F ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b Uniwersytet Medyczny W Lubllnie   (Poland)

Author keywords

Drug toxicity; Phosphodiesterase inhibitors; Pulmonary hypertension

Indexed keywords

PHOSPHODIESTERASE V INHIBITOR;

CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; DRUG CONTRAINDICATION; ERECTILE DYSFUNCTION; FEMALE; HUMAN; MALE; PULMONARY HYPERTENSION; REVIEW;

CARDIOVASCULAR DISEASES; ERECTILE DYSFUNCTION; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; PHOSPHODIESTERASE 5 INHIBITORS;

EID: 79952960661     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Badesch D.B., Hill N.S., Burgess G. et al.: Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J. Rheumatol., 2007, 34, 2417-2422.
2. Boolell M., Gepi-Attee S., Gingell J.C. et al.: Sildenafil, a novel effective oral therapy for male erectile dysfunction. Br. J. Urol., 1996,76, 257-261.
3. Carson C.C., Burnett A.L., Levine L. et al.: The efficacy of sildenafil citrate (Viagra) in clinical populations an update. Urology., 2002, 60, 12-27.
4. Cheitlin M.D., Hutter A.M. Jr., Brindis R.G. et al.: ACC/AHA expert consensus document use of sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology/American Heart Association. J. Am. Coll. Cardiol., 1999, 33, 273.
5. Corbin J.D., Francis S.H., Webb D.J.: Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction. Urology., 2002, 60, supl. 2B, 4-11.
6. Fogari R., Zoppi A., Poletti L. et al.: Sexual activity in hypertensive men treated with valsarían or Carvedilol., a crossover study. Am. J. Hypertens., 2001, 14, 27.
7. Fowler C.J., Miller J.R., Sharief M.K. et al.: A double blind., randomised study of sildenafil citrate for erectile dysfunction in men with multiple sclerosis. J. Neurol. Neurosurg. Psychiatry., 2005, 6, 700-705.
8. Fox K.M., Thadani U., Ma P.T. et al.: Sildenafil citrate does not reduce exercise tolerance in men with erectile dysfunction and chronic stable angina, CAESAR I (Clinical American and European Studies of Angina and Revascularization) investigators. Eur. Heart. J., 2003,24,2206-2212.
9. Galie N., Ghofrani H.A., Torbicki A. et al.: Sildenafil citrate therapy for pulmonary arterial hypertension. N. Engel. J. Med., 2005,353,2148-2157.
10. Glenn D.R., McVicar CM., McClure N. et al.: Sildenafil Improves sperm motility but causes a premature acrosome reaction in vitro. Fertil. Steril., 2007, 87, 1064-1070.
11. Gresser U., Gleiter O.H.: Erectile dysfunction, comparison of efficacy and side effects of the PDE5 inhibitors sildenafil., vardenafil and tadalafil. Eur. J. Med. Res., 2002, 7, 435.
12. He B., Zhang F., Li X. et al.: Meta-analysis of randomized controlled trials on treatment of pulmonary arterial hypertension. Circ. J., 2010, 74, 1458-1464.
13. Herrmann H.C., Chang G., Klugherz B.D. et al.: Hemodynamic effects of sildenafil in men with severe coronary artery disease. N. Engl. J. Med., 2000, 342, 1622-1626.
14. Humbert M., Sibton O., Chaout A. et al.: Pulmonary arterial hypertension in France, results from a national registry. Am. J. Respiro. Crit. Care. Med., 2006, 173, 1023-1026.
15. Idiopathic Pulmonary Fibrosis Clinical Research Network., Zisman D.A., Schwarz M. et al.: A controlled trial of sildenafil In advanced Idiopathic pulmonary fibrosis. N. Engl. J. Med., 2010, 363, 620-628.
16. Ishikura F., Beppu S., Hamada T. et al.: Effects of sildenafil citrate (Viagra) combined with nitrate on the heart. Circulation., 2000, 102, 2516-2521.
17. Jackson G., Benjamin N., Jackson N. et al.: Effects of sildenafil on human hemodynamics. Am. J. Cardiol., 1999, 83, 29C-34C
18. Katz S.D., Parker J.D., Glasser D.B. et al.: Efficacy and safety of sildenafil citrate in men with erectile dysfunction and chronic heart failure. Am. J. Cardiol., 2005, 95, 36-42
19. Kim S., Narayan S., Song J.C. et al.: Tadalafil - an oral selective phosphodiesterase 5 inhibitor for treatment of erectile dysfunction. Formulary., 2003, 37, 289-296.
20. Kloner R.A., Brown M., Prisant L.M. et al.: Effect of sildenafil In patients with erectile dysfunction taking antihypertensive therapy. Am. J. Hypertens., 2001, 14,70-73.
21. Kopka M., Kotowicz J.: The use of sildenafil in erection disorders of neurological origin. Ter. Leki., 2003, 53, 24-27.
22. Laties A., Zrenner E.: Viagra (sildenafil citrate) and ophthalmology. Prog. Retin. Eye. Res., 2002, 21, 485-506.
23. LaValle J.: The COX-2 connection, natural breakthrough treatment for arthritis., Alzhemer's and cancer. Healing Arts Press, Rochester 2001.
24. Lew-Starowicz M.L: Leczenie zaburzeti erekcji za pomoca. inhibitorów PDE5 - skuteczność., satysfakcja i preferencie pacjentów. Prz. Seksuol., 2006, 2, 16-21.
25. Lew-Starowicz Z. (red.): Problémy seksualne w rotných specjalnošciach lekarskich. PZWL., Warszawa 1992.
26. Lu X.L., Xiong C.M., Shan G.L. et al.: Impact of sildenafil therapy on pulmonary arterial hypertension in adults with congenital heart disease. Cardiovasc. Ther., 2010, 28, 350-355.
27. Maytom M.C., Derry F.A., Dinsmore W.W. et al.: A two-part pilot study of sildenafil (VIAGRA) in men with erectile dysfunction caused by spinal cord injury. Spinal. Cord., 1999, 37, 110-116.
28. McDonald J.W., Sadovsky C.L.: Spinal cord injury. Lancet., 2002, 359, 417-425.
29. Michelakis E.D., Tymchak W., Noga M. et al.: Long-temi treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation., 2003, 108, 2066-2069.
30. Nurnberg G.H., Gelenberg A., Hargreave TB. et al.: Efficacy of sildenafil citrate for the treatment of erectile dysfunction in men taking serotonin reuptake inhibitors. Am. J. Psych., 2001, 158, 1926-1928.
31. Oliver JJ., Dear J.W., Webb D.J.: Clinical potential of combined organic nitrate and phosphodiesterase type 5 inhibitor in treatment-resistant hypertension. Hypertension., 2010, 56, 62-67.
32. Ormrod D., Easthope E., Figgit D.P.: Vardenafil. Drugs. Aging., 2002,19, 217-227.
33. Osterioh I., Eardley I., Carson C et al.: Sildenafil, a selective phosphodiesterase (PDE) 5 Inhibitor in the treatment of erectile dysfunction. -InCarson C., Kirby R., Goldstein I. (edts.): Textbook of erectile dysfunction, informa Healthcare, New York, 1999, 285-308.
34. Pickering T.G., Maneia G., Glasser D.B. et al.: Safety of Viagra (sildenafil citrate) in men with erectile dysfunction and arterial hypertension who are taking multiple antihypertensive medications, a post-hoc analysis of five placebo - controlled trials. Am. J. Hypertens., 2002, 15, supl. 1, A55-56.
35. Ramani G.V., Park M.H.: Update on the clinical utility of sildenafil in the treatment of pulmonary arterial hypertension. Drug. Des. Devei. Ther., 2010, 4, 61-70.
36. Reffelman T., Kloner RA.: Therapeutic potential phosphodiesterase 5 inhibition for cardiovascular disease. Circulation., 2003, 108, 239.
37. Rendell M.S., Raifer J., Wicker PA. et al.: Sildenafil for the treatment of erectile dysfunction in men with diabetes a randomized controlled trial. JAMA., 1999,281,421-426.
38. Schermuly R.T., Pullamsetti S.S., Kwapiszewska G. et al.: Phosphodiesterase 1 upregulation in pulmonary arterial hypertension, target for reverse-remodeling therapy. Circulation., 2007, 115, 2331-2339.
39. Seidman S.N., Roose S.P., Menza MA. et al.: Treatment for erectile dysfunction in men with depressive symptoms, results of placebo - controlled trial with sildenafil citrate. Am. J. Psych., 2001, 158, 1623-1630.
40. Zaki S.A., Dadge D., Asif S. et al.: Diagnostic dilemma in a child with congenital heart disease on sildenafil. Indian J. Pharmacol., 2009, 41, 148-149.